Evidence map›Paper›PMID 33078206›Full record

ArticleDiabetologia2021

The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.

Jedidiah I Morton, Jenni Ilomӓki, Dianna J Magliano, Jonathan E Shaw

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Persistent disparities in diabetes medication receipt by socio-economic disadvantage in Australia.Diabetic medicine : a journal of the British Diabetic Association · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jedidiah I MortonBaker Heart and Diabetes Institute, Melbourne, VIC, Australia. jedidiah.morton@baker.edu.au.ORCID 0000-0002-3231-5758
Jenni IlomӓkiSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-0348-9441
Dianna J MaglianoBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.ORCID 0000-0002-9507-6096
Jonathan E ShawBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.ORCID 0000-0002-6187-2203
Baker Heart and Diabetes Institute · AUMonash University · AU

Funding

Australian Government Research Training ProgramMonash University MGESNational Health and Medical Research Council Investigator grantVictorian Government OISP
6 · The paper itself

Abstract

aims/hypothesisIn recent years, several new medications for the treatment of type 2 diabetes have been released and some evidence indicates sociodemographic disparity in their utilisation. We sought to investigate sociodemographic disparities in receipt of diabetes medications across Australia.

methodsThis study included 1,203,317 people with type 2 diabetes registered on the Australian National Diabetes Services Scheme (NDSS) followed from 2007 to 2015. The NDSS was linked to the Australian pharmaceutical claims database. We investigated trends in diabetes medication dispensing and variation in dispensing by sociodemographic strata.

resultsCompared with individuals in the least disadvantaged areas, those in the most disadvantaged quintile were less likely to receive dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) in the first year of availability (OR [95% CI] for most vs least disadvantaged: 0.78 [0.75, 0.82], 0.65 [0.60, 0.71] and 0.89 [0.84, 0.95], respectively). These disparities dissipated over time for DPP4is and SGLT2is but remained significant for GLP-1RAs. The OR (95% CI) of receiving DPP4is, GLP-1RAs and SGLT2is in the first year of availability for people in remote areas vs major cities was 0.46 (0.39, 0.54), 0.46 (0.35, 0.61) and 0.71 (0.59, 0.84), respectively. These disparities remained significant through to 2015. CONCLUSIONS/

interpretationPeople with diabetes in more disadvantaged areas are less likely to receive newer diabetes medications, although this effect decreased over time. However, there are considerable and persistent differences in receipt of newer diabetes medications between major cities and remote areas of Australia. Graphical abstract.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsSocioeconomic FactorsAgedAustraliaDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleHealthcare DisparitiesHumansHypoglycemic AgentsMaleMiddle AgedNeighborhood CharacteristicsRegistriesRural PopulationSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAustraliaDiabetesDPP4 inhibitorsGLP-1RAsHealth services researchMedicationsPharmacoepidemiologySGLT2 inhibitorsSocioeconomic status

Identifiers

PMID33078206
OpenAlexW3093149803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.